X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (145) 145
humans (141) 141
oncology (105) 105
female (77) 77
melanoma (75) 75
middle aged (66) 66
male (65) 65
melanoma - pathology (54) 54
melanoma - drug therapy (46) 46
adult (44) 44
aged (39) 39
cancer (37) 37
article (36) 36
melanoma - genetics (29) 29
skin neoplasms - pathology (28) 28
malignant-melanoma (25) 25
animals (23) 23
prognosis (22) 22
proto-oncogene proteins b-raf - genetics (22) 22
survival (21) 21
mice (20) 20
mutation (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
immunotherapy (19) 19
metastases (19) 19
metastatic melanoma (19) 19
neoplasm staging (19) 19
skin neoplasms - drug therapy (17) 17
therapy (17) 17
abridged index medicus (16) 16
aged, 80 and over (16) 16
antineoplastic agents - therapeutic use (16) 16
melanoma - secondary (16) 16
patients (16) 16
research (16) 16
braf (15) 15
cell biology (15) 15
melanoma - immunology (15) 15
metastasis (15) 15
tumors (15) 15
cell line, tumor (14) 14
melanoma - mortality (14) 14
neoplasm metastasis (14) 14
proto-oncogene proteins b-raf - antagonists & inhibitors (14) 14
treatment outcome (14) 14
melanoma - therapy (13) 13
antineoplastic agents - adverse effects (12) 12
biopsy (12) 12
care and treatment (12) 12
chemotherapy (12) 12
cutaneous melanoma (12) 12
dermatology (12) 12
immunology (12) 12
risk (12) 12
skin neoplasms - genetics (12) 12
surgery (12) 12
expression (11) 11
follow-up studies (11) 11
lymphocytes (11) 11
neoplasms - drug therapy (11) 11
vemurafenib (11) 11
cells (10) 10
melanoma - metabolism (10) 10
skin neoplasms - mortality (10) 10
acquired-resistance (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
combined modality therapy (9) 9
disease progression (9) 9
ipilimumab (9) 9
medicine & public health (9) 9
risk factors (9) 9
skin neoplasms - therapy (9) 9
trial (9) 9
antineoplastic agents - administration & dosage (8) 8
biology (8) 8
breast neoplasms - therapy (8) 8
clinical trials (8) 8
combination (8) 8
lymphatic metastasis (8) 8
melanoma - diagnosis (8) 8
melanoma - surgery (8) 8
mutations (8) 8
neoplasms (8) 8
neoplasms - therapy (8) 8
resistance (8) 8
retrospective studies (8) 8
survival rate (8) 8
apoptosis (7) 7
breast-cancer (7) 7
cd8 antigen (7) 7
drug therapy (7) 7
genetic aspects (7) 7
indoles - pharmacology (7) 7
lung-cancer (7) 7
lymphocytes t (7) 7
medicine, general & internal (7) 7
mek inhibition (7) 7
multidisciplinary sciences (7) 7
pathway (7) 7
phenotype (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 19, pp. 1888 - 1890
Journal Article
Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7547, pp. 373 - 377
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with metastatic melanoma produced a significantly higher response... 
CELL LUNG-CANCER | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | EFFICACY | PATHWAY | SAFETY | KINASE | RESISTANCE | DOSE-ESCALATION TRIAL | RAF INHIBITORS | IMPROVED SURVIVAL | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 8, pp. 707 - 714
Journal Article
Nature, ISSN 0028-0836, 05/2017, Volume 545, Issue 7652, pp. 60 - 65
Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical... 
CRITERIA | MELANOMA | PEMBROLIZUMAB | IMMUNE CHECKPOINT BLOCKADE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | BRAF INHIBITORS | CHRONIC VIRAL-INFECTION | CANCER-THERAPY | IPILIMUMAB | EXHAUSTION | CD8-Positive T-Lymphocytes - cytology | Antibodies, Monoclonal, Humanized - therapeutic use | Melanoma - blood supply | Humans | Ki-67 Antigen - metabolism | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Melanoma - pathology | Phenotype | Antibodies, Monoclonal, Humanized - administration & dosage | Ki-67 Antigen - immunology | Antibodies, Monoclonal, Humanized - pharmacokinetics | Melanoma - immunology | Melanoma - drug therapy | CD8-Positive T-Lymphocytes - metabolism | Female | Programmed Cell Death 1 Receptor - immunology | Antibodies, Monoclonal, Humanized - immunology | CD8-Positive T-Lymphocytes - immunology | Neoplasm Staging | Tumor Burden - immunology | Oncology, Experimental | Melanoma | Physiological aspects | Research | T cells | Tumors | Apoptosis | Cancer | Profiling | PD-1 protein | CD8 antigen | Medical services | Clinical trials | Lymphocytes T | Blood | Metastases | Immunology | Lymphocytes | Immunotherapy | Peripheral blood | Pretreatment | Medical research | Immunoglobulins | T cell receptors | Pharmacology | Patients | Pathology | Cell death | PD-L1 protein | Infiltration | Index Medicus
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 03/2014, Volume 124, Issue 3, pp. 1406 - 1417
Journal Article
Nature, ISSN 0028-0836, 08/2018, Volume 560, Issue 7718, pp. 382 - 386
Journal Article
Cell Reports, ISSN 2211-1247, 09/2013, Volume 4, Issue 6, pp. 1090 - 1099
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2013, Volume 31, Issue 14, pp. 1767 - 1774